about
Intracranial extension of orbital inflammatory pseudotumor: a case report and literature reviewChronic hepatitis C virus infection and neurological and psychiatric disorders: an overviewRevelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotypeThe Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityPatient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.Prognostic indicators in pediatric clinically isolated syndrome.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients.Tumor necrosis factor-alpha and insulin-like growth factor-1 levels in patients with relapsing-remitting multiple sclerosis receiving interferon-beta1a.Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis.Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.Isolated transient blindness and isolated oculomotor nerve palsy secondary to single mesencephalic metastases: report of 2 cases.The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations.Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.Fluctuations of MS births and UV-light exposure.Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic StudyNatalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective studyNormalization of short-chain acylcoenzyme A dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme A dehydrogenase-deficient myopathyUnusual manifestation of vertebral osteoid osteoma: case reportMigraine as possible red flag of PFO presence in suspected demyelinating diseaseNo evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
P50
Q26765396-61D79520-12EF-4099-B868-6421DB4910B0Q28082212-8FB682C2-9F37-4888-8186-0A931309C745Q28245570-2E60E3F0-3747-4E8D-94CC-53B48BC3D34DQ36062456-BB83CA83-CCB3-4ECD-8394-E03562FD81E8Q37235845-A9E2FF7C-8927-4DF9-8A69-F72F037E825FQ38631863-26F69099-810D-4D7C-9076-84DD0CF2F70BQ38821503-D2718269-415D-4637-8390-694FD2E99478Q39692977-A38C8575-37D0-4601-8617-1D498E1F5F29Q40446543-334933C3-6F33-4521-AF44-83243BF7EEFDQ41369754-C64E11AD-53AF-4902-A708-E5983F9F6BD0Q41524426-DB7ED877-D7DF-458E-AE1F-2192D3921C1FQ42340618-AE2B372F-E780-4FC9-81DC-FF298E9B8CB4Q42449729-381DDEB1-67A4-432A-A743-4C475564BE4EQ43164753-35E5E8DA-2623-4182-B5F6-9FBE9BCC4333Q45722939-FE4A50BD-D3A4-45EE-8E19-1BCD17AF2D92Q47865523-385DDB19-62A8-40A6-94A8-D87D5EC9969AQ48192097-50A496E7-CB1A-4A19-814F-D5648BD842D6Q48697261-10BF4320-5AE4-4EB5-A9C5-C4036411F455Q48748004-F9A1C197-E41C-4CD6-A884-1BF90C2291A2Q48983171-D3D7F0DF-FF41-4D10-A4F6-2C1ED41FECC1Q50577133-3E20AE53-E33E-4104-BEAF-03BD51E0F9C2Q51343889-4B926136-3A05-4EF0-B64D-72F4AD1A673AQ51810980-14F4CE1D-FD3F-4A98-B306-2F2454154FE6Q53123917-CEFE604B-CFEC-4D44-A23E-21B261BEBC2EQ57117818-2ADDAD5A-0C20-450C-A925-62F4A0B57087Q62083142-DAC49F27-4D3A-4FC9-810A-2B8A0DED3710Q69715832-1C9D171B-F942-4F7A-BFDA-F33278619FF2Q77699718-AAEC0EEE-0BFC-474F-A20A-CAA6AB95B9BEQ88865994-3A02892F-1F02-4EE0-A3BF-BFE792236F0EQ91794541-8E392BB6-51F4-4BF9-8A3E-F048F8AC58F1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giacomo Lus
@ast
Giacomo Lus
@en
Giacomo Lus
@es
Giacomo Lus
@nl
Giacomo Lus
@sl
type
label
Giacomo Lus
@ast
Giacomo Lus
@en
Giacomo Lus
@es
Giacomo Lus
@nl
Giacomo Lus
@sl
prefLabel
Giacomo Lus
@ast
Giacomo Lus
@en
Giacomo Lus
@es
Giacomo Lus
@nl
Giacomo Lus
@sl
P106
P1153
6602849093
P21
P31
P496
0000-0002-9457-1124